Skip to main content
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics — Investor Relations & Filings

Ticker · MLTX ISIN · KY61559X1045 US Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2022-02-03 Proxy Solicitation & In…
Country US United States of America
Listing US MLTX

About MoonLake Immunotherapeutics

https://moonlaketx.com/

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically identified as a preliminary proxy statement for an extraordinary general meeting of shareholders. It details the business combination agreement, voting matters, share structure changes, and related corporate actions. Proxy statements are materials sent to shareholders to provide information and solicit votes for meetings, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). The document is lengthy (15,000 characters) and contains detailed information typical of a proxy statement, not just an announcement or summary. Therefore, the correct classification is PSI.
2022-02-03 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-03 English
Regulatory Filings 2022
Regulatory Filings
2022-02-02 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Preliminary Proxy Statement on Schedule 14A filed by Helix Acquisition Corp. The letter addresses specific comments on disclosures and revisions made to the proxy statement, including financial projections, risk disclosures, and clinical trial information. The document references amendments to the Preliminary Proxy Statement and discusses compliance with SEC comment letters. It does not contain the proxy statement itself but is a correspondence related to the proxy filing process. Given the nature of the document as a response to SEC comments on a proxy statement, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2022-01-21 English
PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, as indicated by the header and the form type 'PRER14A' and 'Schedule 14A'. It is related to an extraordinary general meeting of shareholders of Helix Acquisition Corp. concerning a Business Combination Agreement and related shareholder votes. Proxy Statements are materials sent to shareholders to provide information and request votes for meetings, which matches the description of Proxy Solicitation & Information Statement filings. The document is lengthy (15,000 characters) and contains detailed information about the business combination, voting matters, and shareholder meeting logistics, consistent with a proxy statement rather than a simple announcement or other filing type. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2022-01-21 English
DEFINITIVE ADDITIONAL MATERIALS
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, specifically labeled as "Definitive Additional Materials" and "Soliciting Material Pursuant to §240.14a-12" related to a proxy statement for a business combination between Helix Acquisition Corp. and MoonLake Immunotherapeutics AG. It includes an investor presentation and detailed information intended to solicit shareholder votes for the proposed transaction. The presence of proxy solicitation language, references to the proxy statement, and solicitation of stockholder approvals clearly indicate this is proxy solicitation material. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not merely an announcement but actual solicitation material.
2022-01-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.